4.5 Article

Anti-Vascular Endothelial Growth Factor Drug Conbercept-Loaded Peptide Hydrogel Reduced Angiogenesis in the Neovascular Age-Related Macular Degeneration

Journal

JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
Volume 18, Issue 1, Pages 277-287

Publisher

AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jbn.2022.3227

Keywords

nAMD; VEGF; Angiogenesis; Conbercept; Hydrogel

Funding

  1. Natural Science Foundation of Xinjiang Province [2017D01C200]

Ask authors/readers for more resources

Age-related macular degeneration (AMD) is a major cause of global blindness, with neovascular form of AMD (nAMD) being responsible for severe visual loss and legal blindness. Conbercept, a Chinese-developed drug, has shown potential for nAMD treatment. The use of a short chain peptide for controlled drug release has been designed to enhance the efficacy of treatment. In vitro experiments have demonstrated the biocompatibility of the peptide and its ability to reduce cell proliferation and tube formation induced by VEGF, indicating its potential for nAMD treatment.
Age-related macular degeneration ( AMD) accounts for 8.7% of the global blindness and neovascular form of AMD (nAMD) occupies a large proportion of severe visual loss and legal blindness caused by AMD with a relatively low incidence rate. Choroidal neovascularization (CNV) is overwhelmingly responsible for the occurrence of nAMD as bleeding and fluid leakage followed by abnormal formation of blood vessels could directly lead to loss of central vision so that reduce the choroidal angiogenesis is an ideal treatment method of nAMD. VEGF is an important cytokine which promote the signaling pathway of angiogenesis and the abnormal expression of VEGF is verified in great many CNV cases. Several anti-VEGF drugs have been widely used in clinical treatments such as ranibizumab, bevacizumab and aflibercept. Conbercept, as an originally developed drug in China, has attracted great attention. For the purpose of better treatment efficacy, our group designed a short chain peptide (Sequence: DDIIIRH-NH2, M.W.880.99) for controlled drug release to remedy the drawback of the short half-time period. The peptide could self-assembled into a stable `hydrogel under pH 7.4 condition and the 3D structure was clearly observed in TEM study. Rheological study exhibited its great injectability so that the hydrogel was a material for intravitreal injection. Statistics exhibited that the hydrogel could release approximately 50% of total conbercept. The In vitro experiments showed that either dose-dependent or the time-dependent incubation with peptide would not decrease the cell viability of HREC, revealing that the peptide was biocompatible. The most important is that co-incubation with HREC obviously reduced the HREC proliferation and tube formation induced by VEGF, ensuring its potential for the treatment efficacy of nAMD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available